Hi Pete,
It all depends on the distribution in the baseline measurements. For the
omalizumab-IgE model, Naoto, Stacey and I used measured baseline IgE as a
covariate on IgE turnover. Baseline IgE was not normally distributed and
was limited by inclusion criteria. The end result was that the bas
Hi Pete,
I think the standard model most of us would use is baseline as a parameter
in the model, and like other parameters it would have a variability between
subjects. What you describe sounds like a covariance between the baseline
parameter and some other parameter. We are used to include such
ilto:owner-nmus...@globomaxnm.com]
On Behalf Of Ken Kowalski
Sent: Wednesday, August 11, 2010 12:12 PM
To: 'Peter Bonate'; nmusers@globomaxnm.com
Subject: RE: [NMusers] Baseline as a covariate
Hi Pete,
In this setting I generally try to first model the baseline response and
perhaps purs
Hi Peter,
I assume from the question that the baseline is the baseline of your
modeled PD measure, not of some other value (like the baseline weight),
and that you model the actual PD measure, not change from the baseline.
Then
- it would be more logical to use the model-predicted baseline;
-
Hi Pete,
In this setting I generally try to first model the baseline response and
perhaps pursue alternative structural model forms. For example, I may
consider a multiplicative relationship rather than an additive relationship
between baseline and placebo/drug effects. However, if the distribut
